Portal de Periódicos da CAPES

Multisystem Inflammatory Syndrome in Children — Initial Therapy and Outcomes

2021; Massachusetts Medical Society; Volume: 385; Issue: 1 Linguagem: Inglês

10.1056/nejmoa2102605

1533-4406

Mary Beth F. Son, Nancy L. Murray, Kevin G. Friedman, Cameron C. Young, Margaret M. Newhams, Leora R. Feldstein, Laura L. Loftis, Keiko M. Tarquinio, Aalok R. Singh, Sabrina M. Heidemann, Vijaya L Soma, Becky J. Riggs, Julie C. Fitzgerald, Michele Kong, Sule Doymaz, John S. Giuliano, Michael Keenaghan, Janet R. Hume, Charlotte V. Hobbs, Jennifer E. Schuster, Katharine N. Clouser, Mark W. Hall, Lincoln Smith, Steven M. Horwitz, Stephanie P. Schwartz, Katherine Irby, Tamara T. Bradford, Aline B. Maddux, Christopher J. Babbitt, Courtney M. Rowan, Gwenn E. McLaughlin, Phoebe H. Yager, Mia Maamari, Elizabeth H. Mack, Christopher L. Carroll, Vicki L. Montgomery, Natasha Halasa, Natalie Z. Cvijanovich, Bria M. Coates, Charles E. Rose, Jane W. Newburger, Manish M. Patel, Adrienne G. Randolph,

Inflammasome and immune disorders

The assessment of real-world effectiveness of immunomodulatory medications for multisystem inflammatory syndrome in children (MIS-C) may guide therapy.